Skip to main content
SpringerLink
Log in

Antirheumatika und Antiphlogistika

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2020

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Albrecht K, Zink A (2017) Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review data from randomized clinical trials and cohort studies. Arthritis Res Ther 19:68. https://doi.org/10.1186/s13075-017-1266-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Alcorn N, Saunders S, Madhok R (2009) Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 32:1123–1134

    Article  CAS  PubMed  Google Scholar 

  • Alten R, Mischkewitz M, Stefanski AL, Dörner T (2020) Januskinase-Inhibitoren – State of the Art im klinischen Einsatz und Zukunftsperspektiven. Z Rheumatol 79:241–254

    Google Scholar 

  • Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, Winthrop KL, Galloway JB (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Baillieres Clin Rheumatol. https://doi.org/10.1093/rheumatology/kez087

    Article  Google Scholar 

  • Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104–2110

    Article  CAS  PubMed  Google Scholar 

  • Charatan F (2002) Arthritis drug should be removed from market, says consumer group. Brit Med J 324:869

    Article  PubMed  PubMed Central  Google Scholar 

  • Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ (2016) Leflunomide use and risk of lung disease in rheumatoid arthritis: a systematic literature review and metaanalysis of randomized controlled trials. J Rheumatol 43:855–860

    Article  PubMed  Google Scholar 

  • Cooper C, Chapurlat R, Al-Daghri N, Herrero-Beaumont G, Bruyère O, Rannou F, Roth R, Uebelhart D, Reginster JY (2019) Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: What does the literature say? Drugs Aging 36(Suppl 1):15–24

    Article  PubMed  PubMed Central  Google Scholar 

  • Coxib and traditional NSAID Trialists’ (CNT) Collaboration (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769–779

    Article  Google Scholar 

  • Cryer B, Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104:413–421

    Article  CAS  PubMed  Google Scholar 

  • Day R (2002) Another selective COX-2 inhibitor: more questions than answers? J Rheumatol 29:1581–1582

    PubMed  Google Scholar 

  • Dhillon S (2017) Tofacitinib: A review in rheumatoid arthritis. Drugs 77:1987–2001

    Article  CAS  PubMed  Google Scholar 

  • European Medicines Agency (2005) Public statement. European medicines agency announces regulatory action on COX-2 inhibitors. http://www.emea.eu.int/htms/hotpress/d6275705.htm (Erstellt: 17. Feb. 2005)

  • European Medicines Agency (2007) Press release. European medicines agency recommends restricted use for piroxicam. http://www.emea.europa.eu/pdfs/human/press/pr/26514407en.pdf (Erstellt: 25. Juni 2007)

  • European Medicines Agency (2012): European Medicines Agency finalises review of recent published data on cardiovascular safety of NSAIDs. Press release 19. Okt. 2012

    Google Scholar 

  • FDA-Statement (2004) FDA-Statement on Naproxen. http://www.fda.gov/bbs/topics/news/2004/new01148.html (Erstellt: 20. Dez. 2004)

  • Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Krüger K (2018) S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Z Rheumatol 77(Suppl 2):35–53

    Article  CAS  PubMed  Google Scholar 

  • Fu JY, Masferrer JL, Seibert K, Raz A, Needlemam P (1990) The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265:16737–16740

    CAS  PubMed  Google Scholar 

  • Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, Tindall E, Triadafilopoulos G, Stromatt SC, Teoh LS (1993) Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 119:257–262

    Article  CAS  PubMed  Google Scholar 

  • Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006(332):1302–1308

    Article  Google Scholar 

  • Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP, Colin-Jones DG (1994) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 323:1075–1052

    Article  Google Scholar 

  • Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693–11697

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • NN (2018) Überdosierung von Methotrexat durch tägliche Gabe der wöchentlichen Dosis: Risikobewertungsverfahren der Europäischen Arzneimittel-Agentur. Arzneimittelbrief 52:34–35

    Google Scholar 

  • Patrono C, Baigent C (2015) Nonsteroidal anti-inflammatory drugs and the heart. Circulation 129:907–916

    Article  Google Scholar 

  • Petri H (2019) Interaktionspotential traditioneller NSAR und der Coxibe. Dtsch Arztebl 116:111–113

    Google Scholar 

  • Piroxicam Rote-Hand-Brief (2007) Neue Anwendungsbeschränkungen für die systemische Anwendung von Piroxicam aufgrund gastrointestinaler Nebenwirkungen und Hautreaktionen. http://www.akdae.de/20/40/Archiv/2007/40-20071011.pdf

  • Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY (2004) Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63:759–766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schmidt M, Lamberts M, Olsen AM, Fosbøll E, Niessner A, Tamargo J, Rosano G, Agewall S, Kaski JC, Kjeldsen K, Lewis BS, Torp-Pedersen C (2016) Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J 37:1015–1023

    Article  CAS  PubMed  Google Scholar 

  • Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O’Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1–26

    PubMed  Google Scholar 

  • Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023–2038

    Article  CAS  PubMed  Google Scholar 

  • Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977

    Article  PubMed  Google Scholar 

  • Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma Prevention with Celecoxib (APC) Study Investigators (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080

    Article  CAS  PubMed  Google Scholar 

  • Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Brit Med J 342(c 7086):1–11

    Google Scholar 

  • Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232–235

    Article  CAS  PubMed  Google Scholar 

  • Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888–1899

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland

    Prof. Dr. med. Rainer H. Böger

  2. Institut für Pharmakologie und Toxikologie der Universität Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland

    Prof. Dr. med. Gerhard Schmidt

Authors
  1. Prof. Dr. med. Rainer H. Böger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gerhard Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rainer H. Böger .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Ulrich Schwabe

  2. Arzneimittelkommission der deutschen Ärzteschaft, Berlin, Berlin, Germany

    Wolf-Dieter Ludwig

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Der/die Herausgeber bzw. der/die Autor(en), exklusiv lizenziert durch Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Böger, R.H., Schmidt, G. (2020). Antirheumatika und Antiphlogistika. In: Schwabe, U., Ludwig, WD. (eds) Arzneiverordnungs-Report 2020. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62168-4_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62168-4_17

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62167-7

  • Online ISBN: 978-3-662-62168-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation